** Shares of drug developer Kymera Therapeutics KYMR.O rise 39.16% to $41.25 premarket
** Company says its experimental oral drug showed robust STAT6 degradation in blood and skin in early-stage trial
** The drug, KT-621, targets STAT6 — a signaling protein that plays a key role in immune response
** Company says results exceeded 90% STAT6 degradation target even at single doses as low as 6.25 mg
** KT-621 impact on biomarkers of Th2 immune response were in line or superior to Sanofi SASY.PA and Regeneron's REGN.O Dupixent - KYMR
** The study finds that KT-621 was as safe as the placebo, with no severe adverse events
** Up to last close, Kymera stock down ~26% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。